Christine is a registered patent attorney who concentrates her practice on patent prosecution, strategic portfolio counseling, and IP due diligence, primarily in connection with biotechnology and small molecule pharmaceuticals innovations. She has extensive experience preparing and prosecuting US and international patent applications, patentability assessments, and freedom-to-operate analyses, and conducting due diligence for both clients and investors.
Prior to joining Mintz, Christine was an associate at an international law firm, where she advised clients on all phases of patent prosecution and IP portfolio management in her areas of focus. She also assisted companies, investors, and banks with IP due diligence for a broad range of private and public financings. Before becoming an attorney, she worked as a patent agent and a patent technical advisor at the firm.
Christine’s doctoral research focused on the study of photochemical reactions using high-energy femtosecond laser pulses and photoelectron spectroscopy. She co-authored articles about this research in The Journal of Physical Chemistry A, The Journal of Chemical Physics, and the Journal of Atomic, Molecular and Optical Physics.
viewpoints
Why companies may want to accelerate marketing approval for their patented drugs in Canada
November 8, 2024 | Blog | By Lee Johnson, PhD, Christine C. Pemberton, PhD
News & Press
A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.
Involvement
- Member, American Chemical Association